UPC CFI 231/2024
30. Mai 2024·EP3831283 · ANALYTE SENSOR DEVICES, CONNECTIONS, AND METHODS
- Verfahrensdetails
- StatusCase Closed (Patent wie erteilt aufrechterhalten)VerfahrensartNichtigkeitKategorieHauptnichtigkeitsklage
- Parteien
- Kläger
- Sibio Technology LimitedUnternehmen
Vertreter- David Por-Clifford Chance Partnerschaft mbB
- Thomas Gniadek-Simmons & Simmons
- Fritz Lahtzmitwirkend
- Oscar Lammemitwirkend-Simmons & Simmons
- Florian Lausmitwirkend
- Diptanil Debbarmamitwirkend-Simmons & Simmons
Beklagte- Abbott Diabetes Care Inc.Unternehmen
Vertreter- Wim Maas-Taylor Wessing
- François Pochart-August Debouzy
- Mehdi Mahammedi-Bouzina-August Debouzy
- Christian Dekoninckmitwirkend-Taylor Wessing
- Faziel Abdulmitwirkend-Taylor Wessing
- Christopher Thornhammitwirkend-Taylor Wessing
- Nigel Stoatemitwirkend-Taylor Wessing
- Geert Theuwsmitwirkend-Taylor Wessing
- Division
- Paris CD
- Technologie
- InstrumentsMedical technology
- Sprache
- English
- Erste Entscheidung
- 21. Juli 2025
| Patent nichtig | Median Tage bis zur ersten Entscheidung | |
|---|---|---|
| Gesamt-UPC | 37% (34/91) | 124 |
| Paris CD | Gesperrt | Gesperrt |
| Richter Paolo Catallozzi | Gesperrt | Gesperrt |
| Richter Tatyana Zhilova | Gesperrt | Gesperrt |
| Richter Renaud Fulconis | Gesperrt | Gesperrt |
Vor dem UPC: Sibio Technology Limited (15 Verfahren)·Abbott Group (67 Verfahren)
Dieser Streit umfasst 9 weitere Verfahren
UPC CoA 884/2025·UPC CFI 781/2025·UPC CFI 780/2025·UPC CFI 230/2025·UPC CFI 491/2024 und 4 weitere
4 weitere Beklagte zum selben oder einem verwandten Patent
UPC CFI 943/2026·UPC CFI 1613/2025·UPC CoA 899/2025·UPC CFI 624/2025
Starten Sie die kostenlose Testphase, um die Ausgänge zu sehen.
- 2025-07-21Revocation ActionÖffentlich
Zusammenfassung: Decision of the Paris Central Division dismissing the revocation action by Sibio Technology Limited against Abbott Diabetes Care Inc. concerning EP 3 831 283 B1 (glucose monitoring device / CGM sensor). All grounds for revocation (lack of novelty and inventive step) failed. The patent is maintained as granted. Abbott (defendant/patentee) awarded costs. Key headnotes: novelty and inventive step are separate grounds and cannot be combined against the same prior art; grounds for revocation of dependent claims must be stated from the outset; Rule 75(3) RoP does not apply when a counterclaim for revocation in a subsequent infringement action is filed after the oral hearing in an earlier revocation action.
Rechtsfragen anzeigen (5)
- Revocation action - novelty and inventive step as separate grounds
- Grounds for revocation of dependent claims
- Late-filed arguments
- Rule 75(3) RoP interaction with parallel proceedings
- CGM sensor patent validity
| Dokumenttitel | Datum | Öffentlich |
|---|---|---|
| DecisionOutcome | 2025-07-21 | Nicht öffentlich |
| final decision | 2025-07-21 | Öffentlich |
| Hearing Reference | 2025-06-05 | Nicht öffentlich |
| Hearing Reference | 2025-06-05 | Nicht öffentlich |
| Outcome of the Order | 2025-05-28 | Nicht öffentlich |
| procedural order | 2025-05-28 | Öffentlich |
| Receipt | 2025-05-05 | Nicht öffentlich |
| Application pursuant to Rule 9 | 2025-05-02 | Nicht öffentlich |
| Order allowing for comments | 2025-05-02 | Nicht öffentlich |
| Outcome of the Order | 2025-04-14 | Nicht öffentlich |
Sibio Technology Limited (Hong Kong) filed a revocation action against Abbott Diabetes Care Inc. (US) seeking to revoke EP 3 831 283 B1, a patent for continuous glucose monitoring sensor devices and connections. The Paris Central Division dismissed the revocation action in full, maintaining the patent as granted: Sibio's novelty attack over WO'896 was inadmissible for failure to provide a separate novelty analysis, and the inventive step attack combining WO'896 and US'440 failed because US'440 provides no pointer to the dramatic design change needed to arrive at the claimed recess-and-opening configuration.
Patent EP 3 831 283 B1 is novel over WO'896 (closest prior art for inventive step) because WO'896 does not disclose the recess in a bottom exterior surface with the connect support received through a distal-facing opening
BeklagterRechtsgrundlage: Art. 54 EPCHinweis: Court found that WO'896 does not anticipate the distinguishing features 1.4 and 1.5 of claim 1.
Claim 1 involves an inventive step: US'440 provides no pointer to motivate or enable the dramatic design change needed to arrive at the claimed invention from WO'896
BeklagterRechtsgrundlage: Art. 56 EPC; problem-solution approachHinweis: Court applied problem-solution: regardless of how the technical problem is formulated, US'440 would not motivate the skilled person to modify WO'896 in the required manner because it does not disclose the relevant distinguishing features and no pointer exists for the dramatic design change required.
Sibio's second line of inventive step argumentation (re-mapping top/base of housing) is inadmissible as late-filed
BeklagterRechtsgrundlage: R. 75 RoPHinweis: Court upheld Abbott's admissibility objection to the second line of argumentation first raised in Sibio's Reply.
Sibio's novelty challenge over WO'896 is inadmissible: merely referencing a document for novelty/inventive step in general terms without a detailed novelty analysis is insufficient
BeklagterRechtsgrundlage: Art. 65 UPCA; R. 206 RoPHinweis: Court held that lack of novelty and lack of inventive step are separate grounds that cannot be absorbed by each other; a detailed analysis only for inventive step does not establish that novelty is separately challenged.
Claim 1 of EP 3 831 283 B1 lacks novelty over WO'896
KlägerRechtsgrundlage: Art. 54 EPC; R. 206 RoPBegründung: Admissibility: Sibio only provided a detailed analysis with respect to inventive step over WO'896; merely indicating a document will be used for novelty and/or inventive step without specific novelty analysis is insufficient to establish a novelty challenge. Substantively also not established.
Claim 1 lacks inventive step starting from WO'896 combined with US'440
KlägerRechtsgrundlage: Art. 56 EPCBegründung: US'440 provides no incentive for the skilled person to make the dramatic design change required; no pointer identified for arriving at the distinguishing features 1.4 and 1.5.
R. 75(3) RoP bars a new counterclaim for revocation concerning the same patent after an earlier revocation action
BeklagterRechtsgrundlage: R. 75(3) RoP; Preamble to RoP para. 4Begründung: R. 75(3) RoP does not apply when a counterclaim for revocation in a subsequent infringement action before a Local Division is filed after the oral hearing in an earlier Central Division revocation action; flexibility and efficiency principle prevails.
Weitere Fälle zu diesem Grundsatz ansehen.
- WO'896 (glucose monitoring prior art)Erfindungsmüh-Kombination
- US'440 (glucose sensor assembly prior art)Erfindungsmüh-Kombination
Claim 1 of EP 3 831 283 B1 (analyte sensor for continuous glucose monitoring) was construed with attention to features 1.4 (recess in a bottom exterior surface) and 1.5 (connect support received through a distal-facing opening into the recess). The mapping proposed by Sibio in the alternative (treating the top of the housing as the base portion) was held unreasonable and inadmissible.